6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Macrophage Migration Inhibitory Factor Limits Renal Inflammation and Fibrosis by Counteracting Tubular Cell Cycle Arrest

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d3791811e243">Renal fibrosis is a common underlying process of progressive kidney diseases. We investigated the role of macrophage migration inhibitory factor (MIF), a pleiotropic proinflammatory cytokine, in this process. In mice subjected to unilateral ureteral obstruction, genetic deletion or pharmacologic inhibition of MIF aggravated fibrosis and inflammation, whereas treatment with recombinant MIF was beneficial, even in established fibrosis. In two other models of progressive kidney disease, global <i>Mif</i> deletion or MIF inhibition also worsened fibrosis and inflammation and associated with worse kidney function. Renal MIF expression was reduced in tubular cells in fibrotic compared with healthy murine and human kidneys. Bone marrow chimeras showed that <i>Mif</i> expression in bone marrow-derived cells did not affect fibrosis and inflammation after UUO. However, <i>Mif</i> gene deletion restricted to renal tubular epithelial cells aggravated these effects. In LPS-stimulated tubular cell cultures, <i>Mif</i> deletion led to enhanced G2/M cell-cycle arrest and increased expression of the CDK inhibitor 1B (p27Kip1) and of proinflammatory and profibrotic mediators. Furthermore, MIF inhibition reduced tubular cell proliferation <i>in vitro</i>. In all three <i>in vivo</i> models, global <i>Mif</i> deletion or MIF inhibition caused similar effects and attenuated the expression of cyclin B1 in tubular cells. <i>Mif</i> deletion also resulted in reduced tubular cell apoptosis after UUO. Recombinant MIF exerted opposing effects on tubular cells <i>in vitro</i> and <i>in vivo</i>. Our data identify renal tubular MIF as an endogenous renoprotective factor in progressive kidney diseases, raising the possibility of pharmacologic intervention with MIF pathway agonists, which are in advanced preclinical development. </p><p class="first" id="d3791811e277"> <div class="fig panel" id="absf1"> <a class="named-anchor" id="absf1"> <!-- named anchor --> </a> <div class="figure-container so-text-align-c"> <img alt="" class="figure" src="/document_file/8c21bbd6-3419-4a95-8bec-6a14aa6d187a/PubMedCentral/image/ASN.2017020190absf1"/> </div> <div class="panel-content"/> </div> </p>

          Related collections

          Author and article information

          Journal
          Journal of the American Society of Nephrology
          JASN
          American Society of Nephrology (ASN)
          1046-6673
          1533-3450
          November 30 2017
          December 2017
          December 2017
          August 11 2017
          : 28
          : 12
          : 3590-3604
          Article
          10.1681/ASN.2017020190
          5698074
          28801314
          8ad2dbeb-9ef4-4e73-b9b8-ca8f0b84b1a1
          © 2017
          History

          Comments

          Comment on this article